Clarus Wealth Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Clarus Wealth Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	-$6K	–	680
2019 Q1	$6K	Hold	100	–	–	﹤0.01%	561
2018 Q4	$5K	Hold	100	–	–	0.01%	582
2018 Q3	$6K	Hold	100	–	–	﹤0.01%	595
2018 Q2	$6K	Buy	+100	New	+$5.8K	﹤0.01%	594

Other funds holding PPH

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

WWM

Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Clarus Wealth Advisors's PPH Position: Q2 2019 in Review

Clarus Wealth Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2019, closing a stake of 100 shares — an estimated $6K sold.

Clarus Wealth Advisors first reported a position in PPH in Q2 2018 and held it in 4 quarters. The position peaked at $6K in Q1 2019. 41 funds tracked by Wall St. Rank hold PPH as of Q2 2019.

Clarus Wealth Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q2 2019 after selling out during the quarter.
Clarus Wealth Advisors sold 100 VanEck Pharmaceutical ETF shares in Q2 2019, an estimated $6K.
Clarus Wealth Advisors first reported a position in VanEck Pharmaceutical ETF in Q2 2018 and held it in 4 quarters.
Clarus Wealth Advisors's VanEck Pharmaceutical ETF position peaked at $6K in Q1 2019.
41 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2019.

Based on Clarus Wealth Advisors's 13F filing for Q2 2019, filed 24 Jul 2019.